Citi Increases Price Target for Gilead Sciences Ahead of Q1 Biopharma Outlook
Citi raised its price target for Gilead Sciences (GILD) to $165 from $156, maintaining a Buy rating ahead of the Q1 biopharma preview. The move follows Gilead's announcement of a $5 billion acquisition of Tubulis GmbH, aimed at strengthening its cancer drug pipeline.
Topics: Biopharma Gilead Sciences M&A Price Target Upgrade Tubulis GmbH